Impact of theCYP2C8*3polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone

Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5

(2011) Rüdiger Kaspera et al.   BIOCHEMICAL PHARMACOLOGY

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

(2011) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

(2011) J. Honkalammi et al.   DRUG METABOLISM AND DISPOSITION

Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study

(2010) Joseph E. Rower et al.   BIOMEDICAL CHROMATOGRAPHY

Drug interactions evaluation: An integrated part of risk assessment of therapeutics

(2010) Lei Zhang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone MetabolismIn Vitro

(2009) Eugen Muschler et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition

(2009) Brian R. Baer et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

(2009) Federico Innocenti et al.   Pharmacogenetics and Genomics

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

(2009) Elizabeth B Daily et al.   PHARMACOGENOMICS

The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

(2008) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS